期刊文献+

静脉用药调配中心在卵巢癌化疗患者中的应用价值初探 被引量:2

A Study on the Application Value of Intravenous Drug Delivery Center for the Ovarian Cancer Patients Treated by Chemotherapy
下载PDF
导出
摘要 目的探讨静脉用药调配中心在卵巢癌化疗患者中的应用价值。方法选取2014年1月~2015年2月于我院接受治疗的80例卵巢癌患者,按照入院先后分为对照组(n=40)与观察组(n=40),观察组行化疗者均由本院静脉用药调配中心严格按照医嘱对所使用药物进行合理配置,对照组则实施常规化疗药物配置,比较干预后两组摆药及配药时间、不合理医嘱及护理执行情况和2年生存情况。结果观察组摆药时间、配药时间均明显短于对照组(P<0.05),观察组出现不合理医嘱及护理执行中配药浓度不当、使用溶媒不当、给药频次不当及存在配伍禁忌的总比例显著低于对照组(P<0.05),观察组1年及2年生存率均明显高于对照组(P<0.05)。结论针对卵巢癌化疗患者,静脉用药调配中心进行统一配置能有效提高化疗药物配置效率,减少药物配置的不合理现象,提高化疗效果。 Objective To investigate the application value of intravenous drug delivery center for chemotherapy of ovarian cancer pa- tients. Methods 80 patients with ovarian cancer were enrolled in our hospital between January 2014 and February 2015. The patients were divided into two groups: control group (n =40) and observation group (n =40). Chemotherapy by the hospital intravenous drug delivery center in accordance with the doctor' s advice on the rational use of drugs strictly, the control group is the implementation of conventional chemo- therapy drug configuration, compared dispensing time, unreasonable orders, nursing implementation and two-year survival of patients of the two groups after the intervention. Results In the observation group, the time of dispensing was shorter than in the control group (P 〈 0.05), the rate of the irrational doctor' s advice and improper dispensing concentration in the nursing implementation, improper use of the solvent, im- proper administration in observation group decreased compared to those in control group (P〈0.05). The 1 - year and 2 - year survival rates of the observation group were significantly higher than those of the control group (P 〈0.05). Conclusion Intravenous drug delivery center is effective to improve the efficiency of chemotherapy drug allocation and reduce the irrationality of drug distribution for ovarian cancer patients with chemotherapy.
作者 柯娟 王秀铭 夏丹 陈琳 马双 KE Juan WANG Xiuning XIA Dan CHEN Lin MA Shuang(Department of lnfusion Center 3 Department of Obstetrics and Gynecology, Shiyan Maternal and Child Health-care Hospital, Shiyan, Hubei, 442000,China 2.Department of Oneology, Dongfeng General Hospital of Shiyan City, Shiyan, Hubei, 442000, Chin Department of Oncology, Taihe Hospital Affiliated to Hubei Medical College, Shiyan, Hubei, 442000, China)
出处 《肿瘤药学》 CAS 2017年第3期375-379,共5页 Anti-Tumor Pharmacy
关键词 静脉用药调配中心 卵巢癌 化疗 Intravenous drug deployment center Ovarian cancer Chemotherapy
  • 相关文献

参考文献2

二级参考文献16

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2Kwon JS, McGahan C, Dehaeck U, et al. The significance of combination chemotherapy in epithelial ovarian cancer [J]. Int J Gynecol Cancer, 2014, 24(2): 226-232. doi: 10. 1097/ IGC. 0000000000000055.
  • 3Torino F, Bamabei A, De Vecchis L, et al. Chemotherapy- induced ovarian toxicity in patients affected by endocrine- responsive early breast cancer [J]. Endocr Relat Cancer, 2012, 19(2): R21-33. doi: 10. 1530/ERC-11-0199.
  • 4Bruchim I, Jarchowsky-Dolberg O, et al. Advanced (>sec- ond) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer [J]. Eur J Obstet Gynecol Reprod Biol, 2013, 166(1): 94-98. doi: 10. 1016/j. ejogrb. 2012. 10. 003.
  • 5Esposito F, Cecere SC, Magazzino F, et al. Second-line chemotherapy in recurrent clear cell ovarian cancer: re- suits from the muhicenter italian trials in ovarian cancer(MITO-9)[J]. Oneology, 2014, 86(5-6): 351-358. doi: 10. 1159/000358730.
  • 6Teo MC. Update on the management and the role of intra- peritoneal chemotherapy for ovarian cancer [J]. Curt Opin Obstet Gynecol, 2014, 26(1): 3-8. doi: 10. 1097/GCO.
  • 7Robinson W, Cantillo E. Debulking surgery and intraperito- neal chemotherapy are associated with decreased morbidity in women receiving neoadjuvant chemotherapy for ovarian cancer [J]. Int J Gynecol Cancer, 2014, 24(1): 43-47. doi: 10. 1097/IGC. 0000000000000009.
  • 8Muallem MZ, Braicu I, Nassir M, et al. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer [J]. Anticancer Res, 2014, 34(1): 393-399.
  • 9Paroli M, Bellati F, Videtta M, et al. Discovery of chemo- therapy-associated ovarian cancer antigens by interrogating memory T cells [J]. Int J Cancer, 2014, 134(8): 1823-1534. doi: 10. 1002/ijc. 28515.
  • 10卢佳,芦芸,杨永秀,王晓慧.紫杉醇脂质体联合卡铂治疗卵巢癌疗效及安全性的系统评价[J].中国循证医学杂志,2012,12(1):42-48. 被引量:39

共引文献29

同被引文献2

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部